Rafael Holdings Subsidiary Submits NDA for Trappsol® Cyclo™

Article summary

Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the FDA for remibetadex to treat Niemann-Pick Disease Type C.